Product
Ambroxol
Aliases
Ambroxol Hydrochloride, Mucosolvan
8 clinical trials
9 indications
Indication
Parkinson's diseaseIndication
Glucocerebrosidase DeficiencyIndication
Dementia with Lewy BodiesIndication
Lewy Body DiseaseIndication
Parkinson's Disease DementiaIndication
Amyotrophic lateral sclerosisIndication
ParkinsonIndication
Gaucher's DiseaseIndication
Type 1Clinical trial
An Open-Label Pilot Study for Assessing the Safety and Efficacy of High-Dose Ambroxol (HDA) in Newly Diagnosed GBA1 Parkinson Disease (PD)Status: Recruiting, Estimated PCD: 2025-02-27
Clinical trial
A Clinical Trial to Demonstrate Clinical Efficacy on Cognitive, Neuropsychiatric and Functional Outcomes of Ambroxol in New and Early Patients With Prodromal and Mild Dementia With LewybodiesStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body DementiaStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-15
Clinical trial
Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease DementiaStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
AMBroxol Therapy for ALS (AMBALS) Trial: a Double-blind, Randomised, Placebo-controlled Phase 2 Clinical Trial of Ambroxol for ALSStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A Randomised, Double-blind, Placebo-controlled, Singlecenter Trial With Ambroxol in Parkinson Patients With a GBA MutationStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement TherapyStatus: Completed, Estimated PCD: 2022-11-30